Novartis launches a partnership with Pfizer-BioNTech for the production of anti-Covid vaccines. The colossus f
armaceutico will invest around 74 million euros in clinical trials in Italy, earmarked for the 207 study programs currently underway and 20 million euros in the south over the next 4 years for the Torre Annunziata hub to improve environmental sustainability. The group reports it in a note
The Swiss Novartis plant in Stein will be involved in this agreement. The Swiss plant will receive the raw mRna active ingredient from Biontech and will proceed with filling in its facility. The finished product will be sent back to Biontech, to then be distributed worldwide. Production will begin in the second quarter, with first deliveries estimated to begin in the third quarter of 2021."
Related news: Novartis signs initial agreement to provide manufacturing capacity for Pfizer-BioNTech COVID-19 vaccine
Vaccine sovereignty? No, subcontracting. Italy doesn't have the technologies or the interest
